Jaundice developing in a patient with hepatitis C4 months after liver transplantation.
Fiel
M Isabel
MI
Department of Pathology, Mount Sinai Medical Center, New York, NY 10029, USA. mariaisabel.fiel@mountsinai.org
Schiano
Thomas
T
D000998:Antiviral Agents / Q000627:therapeutic use*; D017809:Fatal Outcome; D006526:Hepatitis C / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007565:Jaundice / Q000175:diagnosis; D008103:Liver Cirrhosis / Q000601:surgery / Q000821:virology; D016031:Liver Transplantation / Q000009:adverse effects* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011183:Postoperative Complications / Q000175:diagnosis*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use
D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a; D016559:Tacrolimus